Health coaching program for lung and esophageal cancer patients before surgery
Official title: Prehab for Lung and Esophageal Cancer: Optimizing Well-being for Better Outcomes
Run by Nova Scotia Health Authority · NCT06354959 · Data updated 2026-11-12
This study tests a health coaching program to see if it can help lung and esophageal cancer patients improve their health before surgery.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 25 (estimated) |
| Sponsor | Nova Scotia Health Authority Academic / other |
| Locations | 1 site (Halifax, Nova Scotia) |
| Status | Recruiting |
| Started | June 1, 2024 |
| Main results expected | June 1, 2026 |
| Study ends | January 1, 2027 |
| Registry record updated | August 23, 2024 |
| Trial ID | NCT06354959 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults over 18 diagnosed with lung or esophageal cancer who are scheduled for surgery within two weeks and can provide informed consent.
✕Probably not a fit
Patients who are unable to provide informed consent or do not meet the eligibility criteria may not benefit from this program.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study explores a community-based prehabilitation health coaching program designed for individuals diagnosed with lung or esophageal cancer who are scheduled for surgery. The program lasts for 8 weeks and includes personalized coaching on nutrition, smoking cessation, sleep hygiene, and movement, delivered by a Qualified Exercise Professional. Participants will have multiple assessments at baseline, pre-surgery, and post-surgery to evaluate the program's feasibility and effectiveness. The goal is to enhance patients' overall health and well-being before undergoing major surgical interventions.
Why it matters
Potential benefit: If successful, this program could lead to improved surgical outcomes and quality of life for lung and esophageal cancer patients.
How similar studies have gone: Other studies have shown promising results with prehabilitation programs for surgical patients, indicating potential success for this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosed with lung or esophageal cancer * Scheduled to receive surgical intervention in minimum 2-weeks * Surgeon approval * Able to read and write in English * \>18 years of age Exclusion Criteria: * Not able to provide informed consent
Where it's running
-
Victoria General Hospital
Halifax, Nova Scotia, Canada Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
HR20013 for preventing nausea and vomiting in cancer patients receiving chemotherapy
This real-world study tests whether HR20013 helps prevent nausea and vomiting in adults with cancer who are getting chemotherapy.
-
Methylscape test in body fluids for multi-cancer detection in Colombia
A simple blood, urine, or saliva test called Methylscape is being tested to see if it can detect multiple cancers and identify where the signal is coming from, using people with cancer and healthy volunteers in Colombia.
-
Ready for Safe Cancer Treatment (RESET): A comprehensive perioperative program for surgical patients
The RESET program tests a structured, multidisciplinary perioperative plan to improve safety and recovery for adults having planned cancer surgery and older adults having planned non cancer-related surgery.
-
How environment and biology together predict health, aging, and death
Researchers are following adults to see how living conditions and biology together relate to aging and life expectancy, by linking personal health data with environmental and social information over time.
-
Metastatic liver cancer patient registry from multiple Chinese centers
This is a registry that collects real-world data on adults with liver metastases to understand patterns and prognosis and to support future research.
-
TriAdeno and N-803 vaccine in early prostate cancer on active surveillance
A vaccine combo called TriAdeno plus the N-803 drug is being tested to see if it can help slow or stop growth in men with early-stage, low- to intermediate-risk prostate cancer who are being watched rather than treated right away.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.